Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma

Furukawa,Daisuke; Chijiwa,Tsuyoshi; Matsuyama,Masahiro; Mukai,Masaya; Matsuo,Ei‑Ichi; Nishimura,Osamu; Kawai,Kenji; Suemizu,Hiroshi; Nakagohri,Toshio; Ozawa,Soji; Shimada,Kazuaki; Hiraoka,Nobuyoshi; Nakamura,Masato

doi:10.3892/ol.2017.6633

Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma

Authors:
- Daisuke Furukawa
- Tsuyoshi Chijiwa
- Masahiro Matsuyama
- Masaya Mukai
- Ei‑Ichi Matsuo
- Osamu Nishimura
- Kenji Kawai
- Hiroshi Suemizu
- Toshio Nakagohri
- Soji Ozawa
- Kazuaki Shimada
- Nobuyoshi Hiraoka
- Masato Nakamura
View Affiliations

Affiliations: Division of Pathology and Clinical Laboratories, National Cancer Center Research Institute, Tokyo 1040045, Japan, Central Institute for Experimental Animals, Kawasaki, Kanagawa 2100821, Japan, Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan, Department of Surgery, Tokai University Hachioji Hospital, Hachioji, Tokyo 1920032, Japan, Global Application Development Center, Shimadzu Corporation, Kyoto 6048511, Japan, Institute for Protein Research, Osaka University, Suita, Osaka 5650871, Japan, Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Research Institute, Tokyo 1040045, Japan, Department of Regenerative Medicine, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan
Published online on: July 20, 2017 https://doi.org/10.3892/ol.2017.6633
Pages: 3633-3640
Copyright: © Furukawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal carcinoma (PDC) is one of the major causes of cancer‑associated mortality globally due to its high potential for distant metastasis. To understand hematogenous metastasis, the molecular expression profiles of weak metastatic PDC cell subline BxPC‑3 and highly liver‑metastatic cell subline LM‑BxPC‑3 were compared, and zinc finger protein 185 (ZNF185) was identified as a molecule that is upregulated in LM‑BxPC‑3 cells. The aim of the present study was to evaluate the clinicopathological significance of ZNF185 in PDC. Using immunohistochemistry, ZNF185 expression was investigated in 182 patients with PDC, in association with numerous clinicopathological variables. The expression profile of ZNF185 was also characterized using xenograft models. In contrast to parent BxPC‑3 cells in subcutaneous transplanted tumor foci, which only expressed ZNF185 on their plasma membrane (m)ZNF185, LM‑BxPC‑3 cells in liver‑metastatic foci that were formed subsequent to transplantation all expressed cytoplasmic (c)ZNF185. Additionally, 51% of the cells at the periphery of the tumor foci expressed mZNF185. Expression of cZNF185, and of mZNF185 and cZNF185 combined was identified in 93 and 39% of clinical patients with PDC, respectively. Patients with mZNF185‑negative and ‑positive PDC exhibited a median survival time of 30.2 months and 21.3 months, respectively. Multivariate analysis indicated that the expression of mZNF185 is closely associated with a shorter overall survival time. Increased marked venous invasion was more prevalent in patients who were mZNF185‑positive, as compared with patients who were mZNF185‑negative. These data suggest that the expression of mZNF185 is an independent and unfavorable prognosticator in patients with PDC. The results suggested that the amount and subcellular location of ZNF185 are correlated with the position of the cancer cells expressing it within the nests. Additionally, the subcellular location of ZNF185 may be important to its biological function.

View Figures

View References

1	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
2	Hruban RH, Boffetta P, Hiraoka N, Iacobuzio-Donahue C, Kato Y, Kern SE, Klimstra DS, Kloppel G, Maitra A, Offerhaus GJA, et al: Ductal Adenocarcinoma of the Pancreas. In: World Health Organization Classification of Tumours. Pathology & GeneticsTumours of the Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND: IARC; Lyon: pp. 281–291. 2010
3	Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI
4	Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
5	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moor M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
6	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgon-Bourgade S, de la Fouchardiére C, et al: FOLFILINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
7	Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, et al: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013. View Article : Google Scholar : PubMed/NCBI
8	Groot VP, Rezaee N, Wu W, Cameron JL, Fisgman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL and He J: Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. Mar 23–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
9	Yokoyama N, Otani T, Hashidate H, Maeda C, Katada T, Sudo N, Manabe S, Ikeno Y, Tuyoda A and Katayanagi N: Real-time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging: Preliminary results of a prospective study. Cancer. 118:2813–2819. 2012. View Article : Google Scholar : PubMed/NCBI
10	Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, Opendro SS, Inoue K, Michiura T, Ryota H, et al: A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol. 14:142016. View Article : Google Scholar : PubMed/NCBI
11	Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N and Nakamura M: Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/γ_c^null (NOG) mice. Int J Oncol. 31:741–751. 2007.PubMed/NCBI
12	Furukawa D, Chijiwa T, Matsuyama M, Mukai M, Matsuo EI, Nishimura O, Kawai K, Suemizu H, Hiraoka N, Nakagohri T, et al: Zinc finger protein 185 is a liver metastasis-associated factor in colon cancer patients. Mol Clin Oncol. 2:709–713. 2014.PubMed/NCBI
13	Zheng Q and Zhao Y: The diverse biofunctions of LIM domain proteins: Determined by subcellular localization and protein-protein interaction. Biol Cell. 99:489–502. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zhang JS, Gong A and Young CY: ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer. Oncogene. 26:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hamada K, Monnai M, Kawai K, Nishime C, Kito C, Miyazaki N, Ohnishi Y, Nakamura M and Suemizu H: Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice. Int J Oncol. 32:153–159. 2008.PubMed/NCBI
16	Matsuyama M, Wakui M, Monnai M, Mizushima T, Nishime C, Kawai K, Ohmura M, Suemizu H, Hishiki T, Suematsu M, et al: Reduced CD73 expression and its association with altered purine nucleotide metabolism in colorectal cancer cells robustly causing liver metastases. Oncol Lett. 1:431–436. 2010.PubMed/NCBI
17	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. Wiley-Blackwell; Hoboken, NJ: 2011
18	Japan-Pancreas-Society: Classification of Pancreatic Cancer. Kanehara, Tokyo, Japan: 2011
19	Oguro S, Ino Y, Shimada K, Hatanaka Y, Matsuno Y, Esaki M, Nara S, Kishi Y, Kosuge T and Hiraoka N: Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci. 106:1750–1760. 2015. View Article : Google Scholar : PubMed/NCBI
20	Schaller MD: Paxillin: A focal adhesion-associated adaptor protein. Oncogene. 20:6459–6472. 2001. View Article : Google Scholar : PubMed/NCBI
21	Mierke CT: The role of vinculin in the regulation of the mechanical properties of cells. Cell Biochem Biophys. 53:115–126. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yam JW, Tse EY and Ng IO: Role and significance of focal adhesion proteins in hepatocellular carcinoma. J Gastroenterol Hepatol. 24:520–530. 2009. View Article : Google Scholar : PubMed/NCBI
23	Nagano M, Hoshino D, Koshikawa N, Akizawa T and Seiki M: Turnover of focal adhesions and cancer cell migration. Int J Cell Biol. 2012:3106162012. View Article : Google Scholar : PubMed/NCBI
24	Zhao CJ, Du SK, Dang XB and Gong M: Expression of paxillin is correlated with clinical prognosis in colorectal cancer patients. Med Sci Monit. 21:1989–1995. 2015. View Article : Google Scholar : PubMed/NCBI
25	Shi J, Wang S, Zhao E, Shi L, Xu X and Fang M: Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma. J Oral Pathol Med. 39:548–551. 2010.PubMed/NCBI
26	Li HG, Xie DR, Shen XM, Li HH, Zeng H and Zeng YJ: Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J gastroenterol. 11:1445–1451. 2005. View Article : Google Scholar : PubMed/NCBI